Life Sciences & Biotech
Our Clients
Schlich acts for a wide range of life sciences clients who cover the gamut of enterprises from start-up businesses to large multinational corporations, from universities to mature businesses via spin out companies. Every company is unique and thus every organisation has different needs.
Our team of life sciences attorneys tailor the service we provide to match the varying aims of our clients. We are well versed in supporting the different needs of our clients, whether that is supporting a multinational business with a large existing portfolio of patent rights or a developing business founded on protecting unique technical developments.
Life Sciences & Biotech
Claiming and Protecting Your Inventions
Our Schlich attorneys are well versed in understanding and claiming rights to inventions in the life sciences arena. We prepare and file patent specifications for all aspects of life sciences technologies: from stem cell technologies to DNA-editing systems; from improved antibodies to novel microbes; from medical devices to small molecule pharmaceuticals.
Whilst our core expertise is in Europe, we have extensive experience in securing patent rights in the USA, Japan, Canada, Australia, India, China and other major marketplaces. Furthermore, we have a wide network of associates in other jurisdictions with whom we co-operate in order to gain the broadest commercially useful patent rights that we can achieve. In this way, the value of a client’s intellectual property can be best protected and realised.
Start Up Companies
Start-up companies often require significant assistance in ensuring efficient use or resources to add value to the company and obtain useful protection. We understand that patent rights and intellectual property can be the most valuable possessions owned by a start-up. Thus, our role is often to understand and advise on the efficient deployment of resources in order to protect their valuable technical advances and better develop their business.
Developing Businesses
However, sometimes the transition of a business from start-up or spin out to maturity means that in-depth intellectual property advice is required as part of the foundation and organisation of a firm. To achieve this, one of our attorneys can be intimately involved with the early commercial aspirations of our client. Thus, in addition to obtaining patent rights, we can monitor and analyse the patent rights and pending patent claims owned by competitors. We also review and analyse the state of the marketplace and the effect that ongoing deals will have on our client’s business. Thus, we are able to support a developing business through from drafting the original patent applications and guided their prosecution with the support of our associates in the relevant countries.
Large Firms
Multinational corporations may have larger internal departments whose staff have significant experience in relation to filing and prosecution of patent applications. However, multinational breadth means that detailed jurisdiction-specific advice in often needed to obtain optimum protection. While the intention of different national patent systems can be the same, navigation of the differences between jurisdictions will often require a local expert to avoid the pitfalls. This is notably the case when jurisdictions have subtle but important differences in law and practice, e.g. between the USA and the European Patent Organisation. These differences can appear slight, but can have a significant effect on the rights an applicant can obtain.
One example of this is in the drafting and prosecution of patent application relating the developments in and the optimisation of CRISPR technologies. The CRISPR-Cas system is a Nobel-prize winning leap forward in gene editing technology and the pace of its commercial development has been intense. Schlich acts for Intellia Therapeutics, Inc., both in relation to the drafting and prosecution of patent applications relating to the development and improvement of CRISPR-Cas-based gene editing, and also in opposing the patent claims of potential competitors.
Contentious Proceedings
Schlich attorneys are experienced in contentious Proceedings before the European Patent Office (EPO) and before the UK Intellectual Property Office (UKIPO). Our attorneys are skilled in delivering cost-effective advice when considering, preparing, and prosecuting contentious Proceedings. Our focus is always on yielding commercially relevant results for our clients.
By way of example, and to continue the case study above, Schlich attorneys have successfully opposed patent claims for fundamental aspects of the use of the CRISPR system in eukaryotes. Other patents have been opposed, and limited in their scope to versions comprising particular features, such as specific guides, enzymes from unusual organisms, or changes to the enzymes. In this way, our clients are better able to operate in the marketplace. However, appeals are ongoing and Schlich attorneys will be in attendance to continue to defend our client’s position.
Our specialist patent attorneys
Our UK and European Patent Attorneys and Chartered Trade Mark Attorneys have degrees and Ph.Ds from top UK Universities, but are qualified by experience at the coal face of cutting edge, and critically commercial, technologies.
Recent Insights
Read the latest insights from the Schlich team reporting recent cases relevant to the life sciences & biotech sector.
UniQure’s Haemophilia B gene-therapy patent found valid – and infringed by Pfizer
The range of gene-therapies available to patients is ever expanding and it was only a matter of time before a conflict arose that had to be considered by the UK patent courts. Now uniQure has defended its patent for a Haemophilia B gene therapy against a revocation action brought by Pfizer.
The Battle Between NanoString and 10x Genomics Continues with NanoString Taking the Lead Following Successful UPC Revocation Action
The latest revocation action decided on by the Munich Central Division of the UPC gives NanoString the upper hand in their ongoing dispute with 10x Genomics, while also offering a useful insight into how the UPC appear to be approaching the assessment of inventive step
The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting
We perceive a sigh of relief from some patent holders following issue of the US Federal Circuit’s decision in Allergan USA v. MSN Labs, 24-1061 (Fed. Cir. August 13, 2014) (“Allergan”). This decision appears to forestall the revocation of some patents following the concerning precedential Federal Circuit decision In re Cellect (No. 22-1293) (“Cellect”).
What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…
In a recent decision, the EPO’s Boards of Appeal have confirmed the importance of filing data to support arguments relating to sufficiency of disclosure in EPO opposition proceedings. The patent concerned related to a mixture of fish oil and fruit juice which was alleged to have anticancer properties. The opponent argued the constituents required to achieve the anticancer effect were not sufficiently disclosed, but failed to provide enough data to convince the Board of Appeal. Hence, the Board was satisfied the claimed composition was sufficiently disclosed and ordered that the patent be maintained in amended form.
Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims
In this decision the Board has diverged from previous case law establishing that second medical use claims were restricted to products having a chemical mode of action and instead the Board ruled that “substance or composition” should stretch to any product which may be defined by its chemical composition, regardless of the mode of action.
Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO
EPO medical use claims are interpreted to include the physiological or technical effect of the treatment as being a functional feature of the claim. However, this interpretation yields different bars for novelty and sufficiency, as confirmed by EPO TBA Decision T 0209/22.
New Hope for Antibody Claims in the US
However, in a significant development we now report, means-plus-function language for a claim to an antibody complied with both of the USPTO requirements for written description and for the claim not to be indefinite. Where functional language alone is used in US claims, such claims commonly attract written description and enablement objections. Enablement requires that […]
UPC Court of Appeal Suggests the Description is Relevant to Deciding Whether Certain Embodiments Are Excluded from the Scope of the Claims
The question of whether and to what extent the description should be used to interpret the claims of a patent is a disputed topic in patent law, with there being a need to construe the claims as they are written whilst also reading them in the context of the patent as a whole. In its first substantive decision, the UPC’s Court of Appeal suggests the description can be used to decide whether arguably impractical embodiments are excluded from the scope of the claims.
Get in touch
Our team of UK and European Patent Attorneys and Chartered Trade Mark Attorneys are highly knowledgeable and experienced in assisting clients with all aspects of their IP needs.
Contact us now to find out more about how we could help you and your business.